Access to cancer drugs in Canada: Looking beyond coverage decisions

Roger Chafe, Anthony Culyer, Mark Dobrow, Peter C. Coyte, Carol Sawka, Susan O'Reilly, Kara Laing, Maureen Trudeau, Sharon Smith, Jeffrey S Hoch, Steve Morgan, Stuart Peacock, Rick Abbott, Terrence Sullivan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. Data Sources/Study Design: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. Principal Findings: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs. Conclusions: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.

Original languageEnglish (US)
Pages (from-to)27-35
Number of pages9
JournalHealthcare Policy
Volume6
Issue number3
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Canada
Pharmaceutical Preparations
Neoplasms
Health Expenditures
Information Storage and Retrieval
Mouth Neoplasms

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Chafe, R., Culyer, A., Dobrow, M., Coyte, P. C., Sawka, C., O'Reilly, S., ... Sullivan, T. (2011). Access to cancer drugs in Canada: Looking beyond coverage decisions. Healthcare Policy, 6(3), 27-35.

Access to cancer drugs in Canada : Looking beyond coverage decisions. / Chafe, Roger; Culyer, Anthony; Dobrow, Mark; Coyte, Peter C.; Sawka, Carol; O'Reilly, Susan; Laing, Kara; Trudeau, Maureen; Smith, Sharon; Hoch, Jeffrey S; Morgan, Steve; Peacock, Stuart; Abbott, Rick; Sullivan, Terrence.

In: Healthcare Policy, Vol. 6, No. 3, 01.2011, p. 27-35.

Research output: Contribution to journalArticle

Chafe, R, Culyer, A, Dobrow, M, Coyte, PC, Sawka, C, O'Reilly, S, Laing, K, Trudeau, M, Smith, S, Hoch, JS, Morgan, S, Peacock, S, Abbott, R & Sullivan, T 2011, 'Access to cancer drugs in Canada: Looking beyond coverage decisions', Healthcare Policy, vol. 6, no. 3, pp. 27-35.
Chafe R, Culyer A, Dobrow M, Coyte PC, Sawka C, O'Reilly S et al. Access to cancer drugs in Canada: Looking beyond coverage decisions. Healthcare Policy. 2011 Jan;6(3):27-35.
Chafe, Roger ; Culyer, Anthony ; Dobrow, Mark ; Coyte, Peter C. ; Sawka, Carol ; O'Reilly, Susan ; Laing, Kara ; Trudeau, Maureen ; Smith, Sharon ; Hoch, Jeffrey S ; Morgan, Steve ; Peacock, Stuart ; Abbott, Rick ; Sullivan, Terrence. / Access to cancer drugs in Canada : Looking beyond coverage decisions. In: Healthcare Policy. 2011 ; Vol. 6, No. 3. pp. 27-35.
@article{ba42edba48ca43849a89132c186ee5b0,
title = "Access to cancer drugs in Canada: Looking beyond coverage decisions",
abstract = "Objective: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. Data Sources/Study Design: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. Principal Findings: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs. Conclusions: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.",
author = "Roger Chafe and Anthony Culyer and Mark Dobrow and Coyte, {Peter C.} and Carol Sawka and Susan O'Reilly and Kara Laing and Maureen Trudeau and Sharon Smith and Hoch, {Jeffrey S} and Steve Morgan and Stuart Peacock and Rick Abbott and Terrence Sullivan",
year = "2011",
month = "1",
language = "English (US)",
volume = "6",
pages = "27--35",
journal = "Healthcare Policy",
issn = "1715-6572",
publisher = "Longwoods Publishing Corp.",
number = "3",

}

TY - JOUR

T1 - Access to cancer drugs in Canada

T2 - Looking beyond coverage decisions

AU - Chafe, Roger

AU - Culyer, Anthony

AU - Dobrow, Mark

AU - Coyte, Peter C.

AU - Sawka, Carol

AU - O'Reilly, Susan

AU - Laing, Kara

AU - Trudeau, Maureen

AU - Smith, Sharon

AU - Hoch, Jeffrey S

AU - Morgan, Steve

AU - Peacock, Stuart

AU - Abbott, Rick

AU - Sullivan, Terrence

PY - 2011/1

Y1 - 2011/1

N2 - Objective: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. Data Sources/Study Design: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. Principal Findings: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs. Conclusions: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.

AB - Objective: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. Data Sources/Study Design: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. Principal Findings: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs. Conclusions: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.

UR - http://www.scopus.com/inward/record.url?scp=79952904848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952904848&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79952904848

VL - 6

SP - 27

EP - 35

JO - Healthcare Policy

JF - Healthcare Policy

SN - 1715-6572

IS - 3

ER -